Merck & Company (NYSE:MRK) : 12 investment research analysts covering Merck & Company (NYSE:MRK) have an average price target of $62.83 for the near short term. The highest target price given by the Brokerage Firm to the stock is $80 and the lowest target is $53 for the short term. Analysts expect the variance to be within $8.1 of the average price.
Merck & Co. Inc. has dropped 0.12% in the last five trading days, however, the shares have posted positive gains of 3.11% in the last 4 weeks. Merck & Co. Inc. is up 8.16% in the last 3-month period. Year-to-Date the stock performance stands at 10.92%. Also, Equity Analysts at the Jefferies maintains the rating on Merck & Company (NYSE:MRK). The brokerage firm has issued a Hold rating on the shares. The Analysts at the ratings agency lowers the price target from $54 per share to $53 per share. The rating by the firm was issued on June 14, 2016.
Merck & Company (NYSE:MRK) : The consensus on Merck & Company (NYSE:MRK) based on 12 analyst recommendation on the company stock is 2.17, which is interpreted as a Buy recommendation. Zacks Investment Research has issued a rank of 3 which endorses a Hold on the stock. However, 5 brokers have a differing view as they consider the stock to be a Strong Buy at current levels. 7 experts consider that the stocks earnings and the quoted price is in harmony, hence, they give it a Hold rating.
Merck & Company (NYSE:MRK): During Thursdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $57.15 and $56.91 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $57.68. The buying momentum continued till the end and the stock did not give up its gains. It closed at $57.61, notching a gain of 0.98% for the day. The total traded volume was 9,277,691 . The stock had closed at $57.05 on the previous day.
In an insider trading activity, According to the information disclosed by the Securities and Exchange Commission in a Form 4 filing, the officer (EVP & Chief Info Officer) of Merck & Co., Inc., Golestani Clark had sold 39,877 shares worth of $2,180,076 in a transaction dated May 19, 2016. In this transaction, 39,877 shares were sold at $54.67 per share.
Merck & Co., Inc. is a global health care company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products, which it markets directly and through its joint ventures. The Companys Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures. Human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. The Company sells these human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed health care providers. The Animal Health segment discovers, develops, manufactures and markets animal health products, including vaccines. The Companys animal health products are sold to veterinarians, distributors and animal producers.